Prostate cancer laterality does not predict prostate-specific antigen recurrence after radical prostatectomy. 2007

Vladimir Mouraviev, and Leon Sun, and John F Madden, and Janice M Mayes, and Judd W Moul, and Thomas J Polascik
Duke Prostate Center and Division of Urologic Surgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA.

OBJECTIVE To evaluate biologic behaviors of unilateral cancers compared with bilateral cancers on prostate-specific antigen (PSA) recurrence after radical prostatectomy. METHODS Analysis included demographic, clinical, and pathologic parameters of 1184 men who underwent RP for clinically localized prostate cancer at our institution between 2002 and 2006. Final pathologic assessment was performed with particular attention to laterality and percentage of tumor involvement, along with other routine parameters. On the basis of percentage of tumor involvement, all cancer foci were ranked as 5% or less, 5.01% to 10%, 10.01% to 15%, or greater than 15%. Statistical analysis was performed with univariate and multivariate methods. RESULTS Overall, 19.2% of 1184 patients had completely unilateral cancers. Prostate-specific antigen recurrence was revealed in 164 of 1184 patients (13.9%) at a mean (+/- standard deviation) follow-up of 2.7 +/- 2.4 years. Among men who had recurrence, 26 of 227 (11.5%) had unilateral tumors and 138 of 957 (14.4%) had bilateral disease (P = 0.25). The most common characteristics associated with PSA recurrence of unilateral tumors in the Cox model were diagnostic PSA level, prostate weight, and pathologic Gleason score (P <0.05). CONCLUSIONS Unilateral or bilateral prostate cancer did not predict PSA recurrence in men receiving radical prostatectomy. In contrast, baseline PSA level and pathologic Gleason score strongly predicted PSA recurrence.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011468 Prostatectomy Complete or partial surgical removal of the prostate. Three primary approaches are commonly employed: suprapubic - removal through an incision above the pubis and through the urinary bladder; retropubic - as for suprapubic but without entering the urinary bladder; and transurethral (TRANSURETHRAL RESECTION OF PROSTATE). Prostatectomy, Retropubic,Prostatectomy, Suprapubic,Prostatectomies,Prostatectomies, Retropubic,Prostatectomies, Suprapubic,Retropubic Prostatectomies,Retropubic Prostatectomy,Suprapubic Prostatectomies,Suprapubic Prostatectomy
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D017430 Prostate-Specific Antigen A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer. Kallikrein hK3,gamma-Seminoprotein,hK3 Kallikrein,Prostate Specific Antigen,Semenogelase,Seminin,Kallikrein, hK3,gamma Seminoprotein

Related Publications

Vladimir Mouraviev, and Leon Sun, and John F Madden, and Janice M Mayes, and Judd W Moul, and Thomas J Polascik
April 2010, American journal of clinical pathology,
Vladimir Mouraviev, and Leon Sun, and John F Madden, and Janice M Mayes, and Judd W Moul, and Thomas J Polascik
October 1990, The Journal of urology,
Vladimir Mouraviev, and Leon Sun, and John F Madden, and Janice M Mayes, and Judd W Moul, and Thomas J Polascik
July 1999, The Journal of urology,
Vladimir Mouraviev, and Leon Sun, and John F Madden, and Janice M Mayes, and Judd W Moul, and Thomas J Polascik
August 2011, The Journal of urology,
Vladimir Mouraviev, and Leon Sun, and John F Madden, and Janice M Mayes, and Judd W Moul, and Thomas J Polascik
October 2006, The Journal of urology,
Vladimir Mouraviev, and Leon Sun, and John F Madden, and Janice M Mayes, and Judd W Moul, and Thomas J Polascik
July 2005, Japanese journal of clinical oncology,
Vladimir Mouraviev, and Leon Sun, and John F Madden, and Janice M Mayes, and Judd W Moul, and Thomas J Polascik
November 2009, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology,
Vladimir Mouraviev, and Leon Sun, and John F Madden, and Janice M Mayes, and Judd W Moul, and Thomas J Polascik
May 1997, The Urologic clinics of North America,
Vladimir Mouraviev, and Leon Sun, and John F Madden, and Janice M Mayes, and Judd W Moul, and Thomas J Polascik
January 2009, Urologia internationalis,
Vladimir Mouraviev, and Leon Sun, and John F Madden, and Janice M Mayes, and Judd W Moul, and Thomas J Polascik
November 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Copied contents to your clipboard!